HC Wainwright & Co. Reiterates Buy on Biohaven, Maintains $59 Price Target
Biohaven Pharmaceutical Holding Company Ltd. +2.55% Pre
Biohaven Pharmaceutical Holding Company Ltd. BHVN | 52.65 52.80 | +2.55% +0.28% Pre |
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:
BHVN) with a Buy and maintains $59 price target.